

US009179931B2

(12) United States Patent

Janardhan et al.

(54) SHAPE-SET TEXTILE STRUCTURE BASED MECHANICAL THROMBECTOMY SYSTEMS

(71) Applicant: **Insera Therapeutics, Inc.**, Sacramento,

CA (US)

(72) Inventors: Vallabh Janardhan, Dallas, TX (US);

Vikram Janardhan, Sacramento, CA

(US

(73) Assignee: Insera Therapeutics, Inc., Sacramento,

CA (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 246 days.

This patent is subject to a terminal dis-

claimer.

(21) Appl. No.: 14/012,161

(22) Filed: Aug. 28, 2013

(65) Prior Publication Data

US 2014/0277081 A1 Sep. 18, 2014

Related U.S. Application Data

- (63) Continuation of application No. 13/952,982, filed on Jul. 29, 2013, now Pat. No. 8,679,150.
- (60) Provisional application No. 61/798,540, filed on Mar. 15, 2013.
- (51) **Int. Cl.**A61M 29/00 (2006.01)

 A61B 17/3207 (2006.01)

(Continued)

(52) **U.S. CI.** CPC *A61B 17/320725* (2013.01); *A61B 17/221* (2013.01); *A61B 17/22031* (2013.01); *A61B 17/22032* (2013.01); *A61B 2017/2217*

(2013.01);

(Continued)

(10) Patent No.: US 9,179,931 B2

(45) **Date of Patent:** *Nov. 10, 2015

(58) Field of Classification Search

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

3,378,282 A 4/1968 Demler, Sr. 3,381,114 A 4/1968 Nakanuma (Continued)

FOREIGN PATENT DOCUMENTS

EP 0 521 595 1/1993 EP 1 676 545 7/2006 (Continued)

OTHER PUBLICATIONS

6th Annual MedTech Investing Conference, "Venture Capital and Private Equity Investing in Medical Devices and Healthcare Technologies," May 16-17, 2007.


(Continued)


Primary Examiner — Jonathan W Miles (74) Attorney, Agent, or Firm — Knobbe Martens Olson & Bear, LLP

(57) ABSTRACT

A biomedical shape-set textile structure based mechanical thrombectomy systems and methods are described. In one of the embodiments, the mechanical thrombectomy device can be customized to the length of the clot in each patient. In one of the embodiments, the mechanical thrombectomy device because of the textile structure has a very low overall profile or thickness that is less than 0.0125 inches (0.317 mm) and therefore can be deployed within microcatheters with inner lumen diameter as small as 0.014 inches (0.355 mm).

20 Claims, 54 Drawing Sheets





US 9,179,931 B2Page 2

(51)	Int. Cl.				6,066,149			Samson et al.
	A61B 17/221		(2006.01)		6,080,170			Nash et al.
	A61B 17/22		(2006.01)		6,090,118 6,102,890			McGuckin, Jr. Stivland et al.
	A61B 19/00		(2006.01)		6,102,933			Lee et al.
			(2000.01)		6,107,004			Donadio, III
(52)	U.S. Cl.				6,114,653			Gustafson
	CPC	A611	B 2017/22034 (2013.01); A61B	3	6,146,370		11/2000	
			2019/5466 (2013.01))	6,146,396			Konya et al.
			`	,	6,149,682	A	11/2000	Frid
(56)		Referen	ces Cited		6,165,199		12/2000	Barbut
(50)		reicici	ees Cheu		6,165,292		12/2000	Abrams et al.
	U.S.	PATENT	DOCUMENTS		6,168,622			Mazzocchi
	0.5.		50001121115		6,174,330			Stinson
	3,596,545 A	8/1971	Eisenhardt		6,203,561 6,227,436			Ramee et al. Nishikawa et al.
	3,790,744 A		Bowen		6,237,460		5/2001	
	4,030,503 A		Clark, III		6,241,691			Ferrera et al.
	4,334,535 A		Wilson et al.		6,254,633			Pinchuk et al.
	4,560,378 A		Weiland		6,258,115		7/2001	
	4,585,436 A		Davis et al.		6,262,390	В1	7/2001	Goland
	4,778,559 A 4,964,320 A	10/1988	McNeilly		6,281,262			Shikinami
	4,989,606 A		Gehrich et al.		6,290,721		9/2001	
	5,073,694 A		Tessier et al.		6,346,117		2/2002	
	5,108,419 A		Reger et al.		6,348,063		2/2002	Yassour et al. Kurz et al.
	5,160,342 A		Reger et al.		6,350,271 6,369,355			Saunders
	5,171,383 A		Sagae et al.		6,375,668			Gifford et al.
	5,195,408 A		Niehaus		6,383,204		5/2002	
	5,211,183 A		Wilson		6,383,205		5/2002	
	5,234,451 A		Osypka		6,391,044		5/2002	Yadav et al.
	5,265,622 A	11/1993			6,395,014	В1	5/2002	
	5,324,276 A 5,370,609 A		Rosenberg Drasler et al.		6,428,558			Jones et al.
	5,378,234 A		Hammerslag et al.		6,447,531			Amplatz
	5,383,387 A		Chesterfield et al.		6,482,217			Pintor et al.
	5,398,568 A		Worrell et al.		6,506,204 6,511,492			Mazzocchi Rosenbluth et al.
	5,423,849 A	6/1995	Engelson et al.		6,511,504			Lau et al.
	5,449,372 A		Schmaltz et al.		6,514,273			Voss et al.
	5,484,409 A		Atkinson et al.		6,517,888		2/2003	
	5,522,822 A		Phelps et al.		6,530,935		3/2003	Wensel et al.
	5,537,696 A 5,562,641 A		Chartier Flomenblit et al.		6,530,939			Hopkins et al.
	5,573,520 A		Schwartz		6,540,722		4/2003	Boyle et al.
	5,578,074 A		Mirigian		6,544,276		4/2003	Azizi Hopkins et al.
	5,624,508 A		Flomenblit et al.		6,544,279 6,554,848		4/2003	Boylan et al.
	5,645,558 A		Horton		6,563,080		5/2003	Shapovalov et al.
	5,690,120 A		Jacobsen		6,569,183		5/2003	Kim et al.
	5,695,506 A		Pike et al.		6,585,755		7/2003	Jackson et al.
	5,695,507 A 5,697,899 A		Auth et al. Hillman et al.		6,589,263			Hopkins et al.
	5,725,570 A	3/1998			6,589,265			Palmer et al.
	5,725,572 A		Lam et al.		6,602,264 6,605,111			McGuckin, Jr. Bose et al.
	5,733,400 A	3/1998	Gore et al.		6,610,077			Hancock et al.
	5,741,429 A	4/1998	Donadio, III et al.		6,612,012			Mitelberg et al.
	5,766,219 A		Horton		6,626,936			Stinson
	5,780,807 A		Saunders		6,635,070			Leeflang et al.
	5,836,066 A 5,843,051 A	11/1998	Ingram Adams et al.		6,652,576	В1	11/2003	
	5,843,117 A		Alt et al.		6,666,882			Bose et al.
	5,849,037 A	12/1998			6,669,721			Bose et al.
	5,865,816 A	2/1999			6,673,089 6,679,893		1/2004	Yassour et al. Tran
	5,868,708 A	2/1999	Hart et al.		6,682,546			Amplatz
	5,876,568 A		Kindersley		6,689,986			Patel et al.
	5,879,499 A	3/1999			6,692,504	B2	2/2004	
	5,882,444 A		Flomenblit et al.		6,695,813		2/2004	Boyle et al.
	5,895,398 A 5,895,407 A	4/1999 4/1999	Wensel et al. Jayaraman		6,696,666		2/2004	Merdan et al.
	5,893,407 A 5,897,567 A		Ressemann et al.		6,696,667			Flanagan
	5,911.731 A		Pham et al.		6,710,285			Brown et al.
	5,941,869 A		Patterson et al.		6,719,934		4/2004	Stinson Vodfat at al
	5,944,701 A	8/1999	Dubrul		6,740,112		5/2004	Yodfat et al.
	5,951,599 A		McCrory		6,749,560 6,749,619		6/2004 6/2004	Konstorum et al. Ouriel et al.
	5,972,019 A		Engelson et al.		6,773,448	B2	8/2004	
	5,994,667 A		Merdan et al.		6,777,647		8/2004	Messal et al.
	5,996,929 A 6,019,778 A		Mazodier et al. Wilson et al.		6,818,063			Kerrigan
	6,027,863 A		Donadio, III		6,837,901		1/2005	Rabkin et al.
	6,030,406 A		Davis et al.		6,840,950		1/2005	Stanford et al.
	6,030,586 A	2/2000			6,844,603	B2	1/2005	Georgakos et al.

US 9,179,931 B2 Page 3

(56)	References Cited	8,236,042 8,257,421		Berez et al. Berez et al.
U.	S. PATENT DOCUMENTS	8,261,648	B1 9/2012	Marchand et al.
6 940 091 D	2/2005 Carretter at al	8,267,985 8,267,986		Garcia et al. Berez et al.
6,849,081 B: 6,855,153 B:		8,273,101	B2 9/2012	Garcia et al.
6,855,909 B		8,278,593 8,308,712		Bialas et al. Provost et al.
6,860,893 B 6,861,615 B		RE43,882		
6,862,794 B	2 3/2005 Hopkins	8,333,796	B2 12/2012	
6,867,389 B		8,333,897 8,361,095		Bialas et al. Osborne
6,920,677 B: 6,927,359 B:		8,361,138	B2 1/2013	Adams
6,953,472 B	2 10/2005 Palmer et al.	8,394,119 8,308,670		Zaver et al.
6,964,670 B 6,977,355 B		8,398,670 8,398,701		Amplatz et al. Berez et al.
7,004,954 B		8,409,267		Berez et al.
7,029,494 B		8,409,269 8,409,270		Berez et al. Clerc et al.
7,038,334 B: 7,083,640 B:		8,419,658		Eskuri
7,093,416 B	2 8/2006 Johnson et al.	8,419,787		
7,093,527 B		8,444,668 8,500,788		Jones et al. Berez et al.
7,105,003 B: 7,128,073 B		8,529,614	B2 9/2013	Berez et al.
7,128,752 B		8,617,234 8,623,067		Garcia et al. Berez et al.
7,131,986 B: 7,152,605 B:		8,623,007 8,623,071		Lundkvist et al.
7,172,614 B	2 2/2007 Boyle et al.	8,628,564		Berez et al.
7,179,273 B		8,679,150 8,690,907		
7,211,109 B 7,252,680 B		8,715,314	B1 5/2014	Janardhan et al.
7,300,429 B	2 11/2007 Fitzgerald et al.	8,715,315 8,715,316		Janardhan et al. Janardhan et al.
7,306,618 B: 7,306,624 B:		8,715,316 8,715,317		Janardhan et al.
7,344,546 B		8,721,676	B1 5/2014	Janardhan et al.
7,374,564 B	2 5/2008 Brown	8,721,677 8,728,116		Janardhan et al. Janardhan et al.
7,381,198 B: 7,410,491 B:		8,728,117		
7,410,602 B	2 8/2008 Davey et al.	8,733,618		Janardhan et al.
7,462,192 B: 7,476,034 B:		8,735,777 8,747,432		Janardhan et al. Janardhan et al.
7,572,290 B		8,753,371	B1 6/2014	Janardhan et al.
7,582,101 B	2 9/2009 Jones et al.	8,783,151 8,784,446		
7,588,597 B 7,618,434 B		8,789,452		
7,621,870 B	2 11/2009 Berrada et al.	8,790,365 8,705,330		
7,622,070 B: 7,651,514 B:		8,795,330 8,803,030		
7,735,493 B		8,813,625	B1 8/2014	Janardhan et al.
7,763,011 B		8,816,247 8,828,045		
7,780,646 B: 7,786,406 B:		8,845,678	B1 9/2014	Janardhan et al.
7,828,790 B	2 11/2010 Griffin	8,845,679		Janardhan et al.
7,837,726 B: 7,857,844 B:		8,852,227 8,859,934		Janardhan et al. Janardhan et al.
7,875,050 B		8,863,631	B1 10/2014	Janardhan et al.
7,879,062 B		8,866,049 8,869,670		Janardhan et al. Janardhan et al.
7,892,188 B: 7,922,732 B:		8,870,901	B1 10/2014	Janardhan et al.
7,932,479 B	2 4/2011 Bialas et al.	8,870,910 8,872,068		Janardhan et al. Janardhan et al.
7,942,925 B: 7,955,345 B:		8,872,068 8,874,434		Collobert et al.
7,955,449 B		8,882,797	B2 11/2014	Janardhan et al.
7,971,333 B		8,895,891 8,904,914		Janardhan et al. Janardhan et al.
7,989,042 B: 8,003,157 B:		8,910,555	B2 12/2014	Janardhan et al.
8,043,326 B	2 10/2011 Hancock et al.	2001/0031980 2002/0010487		Wensel et al. Evans et al.
8,044,322 B 8,052,640 B		2002/0010487		Zadno-Azizi
8,088,140 B	2 1/2012 Ferrera et al.	2002/0082558	A1 6/2002	Samson et al.
8,092,483 B		2002/0091355 2002/0099436		Hayden Thornton et al.
8,092,486 B: 8,092,508 B:		2002/0099438		Kusleika et al.
8,142,456 B	2 3/2012 Rosqueta et al.	2002/0133111	A1 9/2002	Shadduck
8,147,534 B		2002/0143349		Gifford, III et al. Anderson et al.
8,152,833 B 8,157,833 B		2002/0188314 2002/0193866		
8,192,484 B	2 6/2012 Frid	2002/0194670	A1 12/2002	Hashemi
8,217,303 B	2 7/2012 Baxter et al.	2002/0198550	A1 12/2002	Nash et al.

US 9,179,931 B2 Page 4

(56)	References Cited		2007/0112381			Figulla et al.
ZII	PATENT DOCUM	FNTS	2007/0118165 2007/0135832		5/2007 6/2007	DeMello et al. Wholey et al.
0.5.	IMENT BOCOM	LIVIS	2007/0135833		6/2007	Talpade et al.
2002/0198589 A1	12/2002 Leong		2007/0142903		6/2007	
2003/0004537 A1	1/2003 Boyle et a		2007/0168019 2007/0173921		7/2007 7/2007	Amplatz et al. Wholey et al.
2003/0065356 A1 2003/0097094 A1	4/2003 Tsugita et 5/2003 Ouriel et a		2007/0175521			Martin et al.
2003/0097094 A1 2003/0097710 A1	5/2003 Adrian	и.	2007/0185501		8/2007	Martin et al.
2003/0100945 A1	5/2003 Yodfat et		2007/0197103			Martin et al.
2003/0114919 A1	6/2003 McQuisto	n et al.	2007/0198029 2007/0198030			Martin et al. Martin et al.
2003/0135265 A1 2003/0176884 A1	7/2003 Stinson 9/2003 Berrada et	al	2007/0225749			Martin et al.
2003/0225448 A1	12/2003 Gerberdin		2007/0228023			Kleine et al.
2003/0226833 A1	12/2003 Shapovalo	v et al.	2007/0233174 2007/0265656			Hocking et al. Amplatz et al.
2004/0004061 A1 2004/0004063 A1	1/2004 Merdan 1/2004 Merdan		2007/0288054			Tanaka et al.
2004/0024416 A1	2/2004 Yodfat et	ıl.	2008/0027356			Chen et al.
2004/0044391 A1	3/2004 Porter		2008/0033475		2/2008	
2004/0073293 A1	4/2004 Thompson 4/2004 Chouinard		2008/0065008 2008/0077119			Barbut et al. Snyder et al.
2004/0073300 A1 2004/0088037 A1	5/2004 Choumand		2008/0097393		4/2008	
2004/0089643 A1	5/2004 Jones et a		2008/0097395			Adams et al.
2004/0093015 A1	5/2004 Ogle		2008/0097398 2008/0107641			Mitelberg et al. Kuebler
2004/0098023 A1 2004/0098033 A1	5/2004 Lee et al. 5/2004 Leeflang	rt al	2008/0107041			Quijano et al.
2004/0038033 A1 2004/0118902 A1	6/2004 Adams	t ai.	2008/0221601	A1	9/2008	Huynh et al.
2004/0167613 A1	8/2004 Yodfat et		2008/0228209			DeMello et al.
2004/0168298 A1	9/2004 Dolan et a	1.	2008/0234722 2008/0262487			Bonnette et al. Wensel et al.
2004/0182451 A1 2004/0193140 A1	9/2004 Poirier 9/2004 Griffin et	a1.	2008/0269774			Garcia et al.
2004/0204737 A1	10/2004 Boismier		2008/0275464			Abrams et al.
2004/0220610 A1	11/2004 Kreidler e		2008/0294181 2008/0296274			Wensel et al. Bialas et al.
2004/0225186 A1 2004/0236412 A1	11/2004 Horne, Jr. 11/2004 Brar et al.	et al.	2008/0300673			Clerc et al.
2004/0230412 A1 2005/0015110 A1	1/2004 Biai et al.	al.	2008/0306499		12/2008	Katoh et al.
2005/0021075 A1	1/2005 Bonnette		2008/0312681			Ansel et al.
2005/0035101 A1	2/2005 Jones et a		2009/0025820 2009/0043283		1/2009 2/2009	Adams Turnlund et al.
2005/0050624 A1 2005/0120471 A1	3/2005 Pangramu 6/2005 Lim	yen	2009/0062841		3/2009	Amplatz et al.
2005/0120471 A1 2005/0131522 A1	6/2005 Etinson et	al.	2009/0076540		3/2009	Marks et al.
2005/0133486 A1	6/2005 Baker et a	1.	2009/0082800		3/2009 4/2009	Janardhan Glimsdale et al.
2005/0149108 A1	7/2005 Cox 9/2005 Mazzocch	i at al	2009/0099647 2009/0105737		4/2009	
2005/0192624 A1 2005/0203553 A1	9/2005 Maschke	i et ai.	2009/0105753		4/2009	Greenhalgh et al.
2005/0228417 A1	10/2005 Teitelbaur		2009/0112251		4/2009	
2005/0234474 A1	10/2005 DeMello		2009/0114626 2009/0125097		5/2009 5/2009	Oberg Bruszewski et al.
2005/0236911 A1 2005/0251200 A1	10/2005 Botos et a 11/2005 Porter	l.	2009/0157048		6/2009	Sutermeister et al.
2005/0256563 A1	11/2005 Clerc et a		2009/0172935		7/2009	Anderson et al.
2005/0267510 A1	12/2005 Razack		2009/0188269 2009/0198269		7/2009 8/2009	Attarwala et al. Hannes et al.
2005/0277975 A1 2005/0283186 A1	12/2005 Saadat et . 12/2005 Berrada et		2009/0198209			Drilling et al.
2006/0004346 A1		41.	2009/0221995	A1	9/2009	Harlan
2006/0009799 A1	1/2006 Kleshinsk		2009/0248071			Saint et al.
2006/0020286 A1	1/2006 Niermann 2/2006 Anderson		2009/0264985 2009/0275974			Bruszewski Marchand et al.
2006/0030878 A1 2006/0047286 A1	3/2006 Anderson 3/2006 West	et al.	2009/0287120			Ferren et al.
2006/0070516 A1	4/2006 McCullag		2009/0297582			Meyer et al.
2006/0100687 A1	5/2006 Fahey et a		2009/0306702 2009/0306762			Miloslavski et al. McCullagh et al.
2006/0116712 A1 2006/0116713 A1	6/2006 Sepetka et 6/2006 Sepetka et		2009/0312834			Wood et al.
2006/0122687 A1	6/2006 Bassler et		2009/0318892			Aboytes et al.
2006/0136043 A1	6/2006 Cully et a		2010/0010622 2010/0023034			Lowe et al. Linder et al.
2006/0161198 A1 2006/0161253 A1	7/2006 Sakai et a 7/2006 Lesh	•	2010/0023034			Levy et al.
2006/0206196 A1	9/2006 Porter		2010/0030256			Dubrul et al.
2006/0206200 A1	9/2006 Garcia et		2010/0049240		2/2010	
2006/0229638 A1	10/2006 Abrams et		2010/0069882 2010/0069948		3/2010 3/2010	Jennings et al. Veznedaroglu et al.
2006/0229645 A1 2006/0241739 A1	10/2006 Bonnette 10/2006 Besselink		2010/0009948			Huang et al.
2006/0264904 A1	11/2006 Kerby et a		2010/0114017		5/2010	Lenker et al.
2006/0276887 A1	12/2006 Brady et a		2010/0131000			DeMello et al.
2007/0016233 A1	1/2007 Ferrera et		2010/0152834			Hannes et al.
2007/0027522 A1 2007/0034615 A1	2/2007 Chang et a 2/2007 Kleine	ш.	2010/0191319 2010/0193485			Lilburn et al. Anukhin et al.
2007/0034015 A1 2007/0045255 A1	3/2007 Kleine et	ıl.	2010/0217276			Garrison et al.
2007/0060880 A1	3/2007 Gregorich	et al.	2010/0217303	A 1		Goodwin
2007/0060942 A2	3/2007 Zadno-Az	izi	2010/0230391	A1	9/2010	Baxter et al.

(56)	Referen	nces Cited		FOREIGN PATENT DOCU	MENTS
U.S.	. PATENT	DOCUMENTS	EP	1 904 217 3/2013	
2010/0262221 A1	10/2010	Schafer et al.	GB WO	667071 2/1952 WO 2004/093738 11/2004	
2010/0280592 A1		Shin et al.	WO	WO 2007/011353 1/2007	
2010/0318097 A1 2011/0036820 A1		Ferrera et al. Merdan		OTHER PUBLICATION	NS
2011/0046719 A1	2/2011		A 1-1	4. Il +	+ DV ACCLII DIZ
2011/0056350 A1		Gale et al.		tt Laboratories, "Xact Carotid Stent Sys id Stent System, 2006 Clinical Update f	
2011/0060359 A1 2011/0060400 A1		Hannes et al. Oepen et al.		is et al., "Guidelines for the Early Manag	
2011/0077620 A1	3/2011	deBeer	Ische	nic Stroke: A Scientific Statement from	the Stroke Council of
2011/0082493 A1 2011/0087147 A1		Samson et al. Garrison et al.		merican Stroke Association," Stroke, 20	03, vol. 34, pp. 1056-
2011/003/14/ A1 2011/0094708 A1		Cardone	1083. Adam	s et al., "Guidelines for the Early Manag	rement of Patients with
2011/0125132 A1		Krolik et al.		mic Stroke—2005 Guidelines Update—	
2011/0125181 A1 2011/0152993 A1		Brady et al. Marchand et al.		he Stroke Council of the American Strok	e Association," Stroke,
2011/0160757 A1		Ferrera et al.		vol. 36, pp. 916-923.	2000
2011/0160760 A1 2011/0160761 A1		Ferrera et al. Ferrera et al.		tor Retrieval Device Product Brochure, et al., "A Novel, Self-Expanding, Nitir	
2011/0100701 A1 2011/0190797 A1		Fulkerson et al.		ctory Intracranial Atherosclerotic Ster	
2011/0190868 A1	8/2011	Ducke et al.		" http://stroke.ahajournals.org/, Americ	an Heart Association,
2011/0203446 A1 2011/0208227 A1		Dow et al. Becking		2007, pp. 1531-1537. n Scientific, "Excelsior 1018 Microcath	neter For Peak Perfor
2011/0200227 A1 2011/0210108 A1		Bialas et al.		e in GDC Delivery," 2000.	ieter, For Feak Ferror-
2011/0213403 A1		Aboytes		n Scientific, "Excelsior 1018 Microca	theter, Neurovascular
2011/0238041 A1 2011/0264133 A1		Lim et al. Hanlon et al.		ss," 2004.	4 . 37 . 1
2011/0265943 A1		Rosqueta et al.		n Scientific, "Excelsior SL-10 Microcass," 2004.	itheter, Neurovascular
2011/0283871 A1	11/2011			n Scientific, "Excelsior SL-10 Mi	crocatheter, The 10
2011/0295359 A1 2011/0307072 A1		Clerc et al. Anderson et al.	Micro	catheter with a 14 Lumen," 2002.	
2012/0022579 A1	1/2012	Fulton		n Scientific, "FilterWire EX, Emboli	c Protection System,
2012/0029616 A1 2012/0055614 A1		Guerriero et al. Hancock et al.		ction for Use," Apr. 2004. n Scientific, "Neuroform ² Microdeliver	v Stent System Tech-
2012/0057813 A1		Von Oepen		Bulletin No. 1—Parent Vessel Protection	
2012/0065660 A1		Ferrera et al.	Bosto	n Scientific, "Neuroform2 Microdel	
2012/0083824 A1 2012/0116443 A1		Berrada et al. Ferrera et al.	Neuro	ovascular Reconstruction," 2004. n Scientific, "Neuroform ³ Microdeliver	y Stant System Confi
2012/0158124 A1	6/2012	Zaver et al.		Begins with Control," 2005.	y Stellt System, Colli-
2012/0164157 A1		Kuebler Fogarty et al.	Bosto	n Scientific, "Pre-Shaped Microcathete	ers, Product Selection
2012/0179192 A1 2012/0197283 A1		Marchand et al.		e," 2004. n Scientific, "Renegade 18 Microca	theter Neurovaccular
2012/0209312 A1		Aggerholm et al.		ss," 2004.	meter, recurovascular
2012/0231414 A1 2012/0232655 A1		Johnson Lorrison et al.		n Scientific, "Synchro Guidewires, N	eurovascular Access,"
2012/0239066 A1		Levine et al.	2004. Bosto	n Scientific, "Tracker Excel-14 Microca	otheter Engineered for
2012/0239074 A1		Aboytes et al.		Coil Delivery," 1998.	infector, Engineered for
2012/0245517 A1 2012/0259404 A1	9/2012 10/2012	Tieu et al.		n Scientific, "Tracker Excel-14 Microca	atheter, Neurovascular
2012/0265238 A1	10/2012	Hopkins et al.		ss," 2004. n Scientific, "Transend Guidewires, N	eurovascular Access."
2012/0271337 A1 2012/0271403 A1	10/2012 10/2012	Figulla et al.	2003.	in setemine, Transent Suite mes, 1.	outo rusounu 11000ss,
2012/02/1403 A1 2012/0273467 A1		Baxter et al.		y et al., "Advancements in Braided Mater	
2012/0277850 A1	11/2012	Bertini		SAMPLE Symposium, May 2001, pp. 2- nut Medical Technologies, Inc., "Instru	
2012/0283768 A1 2012/0290067 A1		Cox et al.	Alliga	tor Retrieval Device (ARD)," 2005.	, ,,
2012/0290007 A1 2012/0316598 A1		Cam et al. Becking et al.		entric Medical, "Instructions for Use, C	oncentric Micro Cath-
2012/0330347 A1	12/2012	Becking et al.		, 2003. entric Medical, "Instructions for Us	se. MERCI retriever
2013/0030460 A1		Marks et al.		66," 2004.	,, name i i i i i i i i i i i i i i i i i i i
2013/0060323 A1 2013/0066357 A1		McHugo Aboytes et al.		s Corporation, "Cordis CarotidSystem,	
2013/0085515 A1		To et al.		Expanding Stent and Cordis Angioguewire System," 2004.	iard Emboli Capture
2013/0092298 A1		Bregulla et al.		s Corporation, "Cordis CarotidSystem, T	Technical Specification
2013/0096587 A1 2013/0167960 A1		Smith et al. Pethe et al.		roduct Codes," 2006.	OV Toohnical Specif
2013/0107900 A1 2013/0220610 A1		Mosing et al.		s Corporation, "Cordis CarotidSystem I is and Product Codes," 2007.	x, recuircai specifi-
2013/0240096 A1	9/2013	Browne et al.	Cordi	s Endovascular, "Diagnosing Carotid	
2013/0327469 A1 2014/0128905 A1		Pingleton et al. Molaei		ng Cause of Stroke," Sample News Ar	ticle #1: "Diagnosis,"
2014/0128903 A1 2014/0155908 A1		Rosenbluth et al.		or earlier. Shield, "Xact, Customized for Carotid A	arteries, The Barewaire
2014/0324091 A1		Rosenbluth et al.		ution is Here," 2005.	•

(56)References Cited

OTHER PUBLICATIONS

ev3, "ev3 Carotid Innovations, Redefining Confidence, See what you've been missing . . . ", ev3 The Endovascular Company, 2008 or earlier.

Furlan et al., "Intra-arterial Prourokinase for Acute Ischemic Stroke, The PROCT II Study: A Randomized Controlled Trial," JAMA, Dec. 1, 1999, vol. 282, Issue 21, pp. 2003-2011.

Henkes et al., "A New Device for Endovascular Coil Retrieval from Intracranial Vessels: Alligator Retrieval Device", AJRN Am J. Neuroradiol, Feb. 2006, vol. 27, pp. 327-329.

Micro Therapeutics, Inc., "Mirage .008", Hydrophilic Guidewire,

Micrus Endovascular, "WATUSI guidewire, Let's Dance," 2006. Rymer et al., "Organizing regional networks to increase acute stroke intervention", Neurological Research, 2005, vol. 27, Issue 1, pp. S9-S16.

Sarti et al., "International Trends in Mortality From Stroke, 1968 to 1994", http://stroke.ahajournals.org/, American Heart Association, Inc., Apr. 20, 2000, pp. 1588-1601.

University of Minnesota, "Design of Medical Devices Conference,"

Apr. 17-19, 2007. Yadav, "Carotid stenting in high-risk patients: Design and rationale of the SAPPHIRE trial", Cleveland Clinic Journal of Medicine, Jan. 2004, vol. 71, Issue 1, pp. S45-S46.

Yadav et al., "Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk Patients," The New England Journal of Medicine, Oct. 7, 2004, vol. 351, Issue 15, pp. 1493-1501 & 1565-

U.S. Appl. No. 60/980,736, filed Oct. 17, 2007.

U.S. Appl. No. 61/044,392, filed Apr. 11, 2008.

U.S. Appl. No. 61/015,154, filed Dec. 19, 2007.

U.S. Appl. No. 60/989,422, filed Nov. 20, 2007.

U.S. Appl. No. 61/019,506, filed Jan. 7, 2008.

U.S. Appl. No. 60/987,384, filed Nov. 12, 2007.

U.S. Appl. No. 61/129,823, filed Jul. 22, 2008. U.S. Appl. No. 61/202,612, filed Mar. 18, 2009.

US 6,348,062, 02/2002, Hopkins et al. (withdrawn)




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig 8.




Fig. 9




Fig. 10




Fig. 11




Fig. 12




Fig. 13




Fig. 14a




Fig. 14b



Fig. 15A




Fig. 15B




Fig. 15C




Fig. 16




Fig. 17




Fig. 18

Nov. 10, 2015




Fig. 19




Fig. 20

US 9,179,931 B2




Fig. 21




Fig. 22




Fig. 23




Fig. 24




Fig. 25




Fig. 26




Fig. 27A




Fig. 27B




Fig. 28




Fig. 29




Fig. 30




Fig. 31




Fig. 32




Fig. 33




Fig. 34




Fig. 35

Pattern A **4-3**

Fig. 36

Pattern B




Fig. 37




Fig. 38




Fig. 39




Fig. 40




Fig. 41




Fig. 42





Fig. 43






Fig. 45

Nov. 10, 2015




Fig. 46




Fig. 47




Fig. 48




Fig. 49




Fig. 50

SHAPE-SET TEXTILE STRUCTURE BASED MECHANICAL THROMBECTOMY SYSTEMS

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 13/952,982, filed Jul. 29, 2013, which claims priority benefit of U.S. Provisional Patent App. No. 61/798,540, filed on Mar. 15, 2013, and the present application claims priority benefit of U.S. Provisional Patent App. No. 61/798,540, filed on Mar. 15, 2013.

Any and all applications for which a foreign or domestic priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by 15 reference under 37 C.F.R. §1.57.

FIELD

The present disclosure generally relates to devices, sys- 20 tems, methods for making, and methods for use in thrombectomy. Several embodiments relate to systems and methods for providing novel approaches for stroke treatment.

BACKGROUND

Stroke is the leading cause of long term disability in the United States and the second leading cause of death worldwide with over 4.4 million deaths in a year (1999). There are over 795,000 new strokes every year in the United States. 30 Around 85% of all strokes are acute ischemic strokes caused from a blockage in a blood vessel or a blood clot occluding a blood vessel. In 1996, the FDA approved a thrombolytic drug to dissolve blood clots called recombinant tissue plasminogen activator (r-tpa). Despite practice guidelines from mul- 35 tiple national organizations stating the intravenous r-tpa is the standard of care for patients with acute ischemic stroke within 3 hours from symptom onset, only 3-4% of patients with acute ischemic stroke received this drug in the United States. Unlike intravenous r-tpa, catheter-based therapies for 40 the figures and described in detail below. mechanical thrombectomy can be used for up to 8 hours or beyond from acute ischemic stroke symptom onset and could benefit more people. With advances in regional stroke networks, there are more and more stroke patients who are getare as high as 21.6%.

SUMMARY

Blood clots can range from 5 mm to greater than 55 mm. In 50 addition, blood clots can extend from one vessel diameter to another vessel diameter. There is clearly an unmet need currently for a mechanical thrombectomy device that is gentle and safe on the fragile human blood vessels, that can be customized to the length of the clot or clot burden using the 55 same device by the operator, that can be visualized with ease under X-ray fluoroscopy, that can reach the smallest of human blood vessels, that can be compatible with torsional rasping of the clot, and/or have bonding zones or attachment points that are strong even between dissimilar metals or alloys to 60 avoid the risk of any fracture points, as well as have flexible delivery systems that have good proximal support and good distal flexibility. Several embodiments of the invention provide one or more of the advantages above. In some embodiments, all of the advantages above are provided.

In several embodiments, the device is particularly beneficial because it includes one or more of the following advan2

tages: (i) adapted for and gentle on the fragile blood vessels instead of an expansile laser-cut stent based mechanical thrombectomy device; (ii) tapered to mimic the tapering of the human blood vessels thereby allowing for the use of a single tapered device to remove blood clots extending across different tapering blood vessel diameters; (iii) allows for flexibility during deployment and retrieval in tortuous human blood vessels thereby allowing for longer usable lengths of the device; (iv) comprises a long usable length can be customized to the length of the clot or the clot burden without having to use multiple devices to remove the clot in piece meal; (v) a textile structure based mechanical thrombectomy device allows for torsional rasping of the textile structure around the blood clot to entrap the clot and retrieve it; (vi) allows for filtering distal emboli or debris that may be released; (vii) employs processes to bond the textile structure and the delivery system allow for bonding of dissimilar metals or alloys; (viii) comprises an inlay bonding approach of the textile structure with the delivery system, which allows for a low overall profile and outer diameter of the mechanical thrombectomy device in the collapsed configuration to be less than e.g., 0.0125 inches (0.317 mm); (ix) low overall profile and outer diameter of the mechanical thrombectomy device in the collapsed configuration allows for the device to be deployed with a microcatheter that has an inner lumen diameter of e.g., 0.014 inch or greater (0.355 mm); (x) patterns of radio-opaque filaments or wires to achieve maximal radioopacity and visibility for the operator during X-ray fluoroscopy; (xi) multiple transition points for the laser-cut delivery system or hypotube, which allows for distal flexibility and proximal support as well as supports the ability to perform torsional rasping of the clot; and/or (xii) the laser-cut hypotube with multiple transition points is incorporated as the core braid for the wall of the microcatheter, which allows for distal flexibility and proximal support for allowing the safe and effective deployment of the textile structure based mechanical thrombectomy device.

Various embodiments of the present invention are shown in

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is a schematic diagram illustrating the 2D view of ting access to intra-arterial thrombolysis and therapies, and 45 one of the embodiments with a spherical tapered textile struc-

> FIG. 2 is a schematic diagram illustrating the 3D perspective view of one of the embodiments with a spherical tapered textile structure.

> FIG. 3 is a schematic diagram illustrating the 2D view of one of the embodiments with an oblong tapered textile struc-

> FIG. 4 is a schematic diagram illustrating the 3D perspective view of one of the embodiments with an oblong tapered textile structure.

> FIG. 5 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical and oblong interspersed tapered textile structure.

FIG. 6 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical non-tapered textile

FIG. 7 is a schematic diagram illustrating the 2D view of one of the embodiments with an oblong non-tapered textile structure.

FIG. 8 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical and oblong interspersed non-tapered textile structure.

- FIG. 9 is a schematic diagram illustrating the 2D view of one of the embodiments with cylindrical wide-mouthed distal tip textile structure.
- FIG. 10 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed 5 distal tip textile structure.
- FIG. 11 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with a spherical or oblong distal filter textile struc-
- FIG. 12 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with a spherical distal and proximal filter textile
- FIG. 13 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with an oblong distal and proximal filter textile
- FIG. 14A is a schematic diagram illustrating the wires 20 positioned on the yarn to develop a biomedical textile structure in one of the embodiments.
- FIG. 14B is a schematic diagram illustrating the braid carrier set up mechanism for the position of the wires on the yarn to develop a biomedical textile structure in one of the 25 embodiments.
- FIG. 15A is a photograph illustrating the wires being braided into a biomedical textile structure on the yarn in one of the embodiments.
- FIG. 15B is a photograph illustrating the wires being knitted into a biomedical textile structure in one of the embodi-
- FIG. 15C is a photograph illustrating the wires being woven into a biomedical textile structure in one of the embodiments.
- FIG. 16 is a photograph illustrating the primary tubular shape set textile structure in one of the embodiments.
- FIG. 17 is a schematic diagram illustrating the primary shape setting into the necessary geometries needed to develop the shape-set textile structures in one of the embodiments.
- FIG. 18 is a photograph illustrating the mandrel used for braiding on the yarn that is then used for primary shape setting into the necessary geometries needed in one of the embodi-
- FIG. 19 is a photograph illustrating secondary shape set- 45 ting into the necessary geometries needed to develop the shape-set textile structure in one of the embodiments.
- FIG. 20 is an X-ray photograph illustrating one of the embodiments where there is grouping of multiple radioopaque filaments or wires together to form an inter-twining 50 thick band for maximal radio-opacity during fluoroscopy.
- FIG. 21 is an X-ray photograph illustrating single filaments inter-twined to provide radio-opacity during fluoroscopy in one of the embodiments.
- FIG. 22 is an X-ray photograph illustrating double fila- 55 ments inter-twined to provide radio-opacity during fluoroscopy in one of the embodiments.
- FIG. 23 is a photograph illustrating the need for postprocessing of the free end of the textile structure to keep the filaments or wires from fraying in one of the embodiments. 60
- FIG. 24 is a schematic diagram illustrating the appearance of the free end of the textile structure after laser cutting the free end to keep the filaments or wires from fraying in one of the embodiments.
- FIG. 25 is a schematic diagram illustrating the inlay bond- 65 ing approach between the shape-set textile structure and the delivery system using solder in one of the embodiments.

- FIG. 26 is a schematic diagram illustrating the overall ratio of the cross-sectional area between the filaments or wires of the textile structure and the bonding agent in one of the embodiments.
- FIG. 27A is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure and delivery system using epoxy agents in one of the embodi-
- FIG. 27B is a photograph illustrating the inlay bonding approach between the shape-set textile structure and delivery system using epoxy agents in one of the embodiments.
- FIG. 28 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure and delivery system using a pinched ring as well as a bonding agent in one of the embodiments.
- FIG. 29 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure and delivery system using a pinched tube as well as a bonding agent in one of the embodiments.
- FIG. 30 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure and the distal end of the delivery system using solder in one of the embodiments.
- FIG. 31 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure and the distal end of the delivery system using epoxy in one of the embodiments.
- FIG. 32 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure and the non-laser cut distal tip of the delivery system using epoxy in one of the embodiments.
- FIG. 33 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure and the distal end of the delivery system using epoxy and heat shrink tubing in one of the embodiments.
 - FIG. 34 is a schematic diagram illustrating the overlay bonding approach between the distal neck of the shape-set textile structure and the distal end of the delivery system using bonding agent in one of the embodiments.
 - FIG. 35 is a photography illustrating the angled flexible laser-cut hypotube delivery system in one of the embodi-
 - FIG. 36 is a schematic diagram illustrating dimensions for laser-cut Pattern A in one of the embodiments.
 - FIG. 37 is a schematic diagram illustrating dimensions for laser-cut Pattern B in one of the embodiments.
 - FIG. 38 is a schematic diagram illustrating the directional stagger of laser-cut Pattern A and Pattern B in one of the embodiments.
 - FIG. 39 is a schematic diagram illustrating the interspersed laser-cut Pattern A and B in one of the embodiments.
 - FIG. 40 is a schematic diagram illustrating the interspersed laser-cut Pattern A and B with the inter-pattern stagger in one of the embodiments.
 - FIG. 41 is a schematic diagram illustrating the edges of the kerf in the angled laser-cut delivery system or hypotube are rounded or sharp in one of the embodiments.
 - FIG. 42 is a schematic diagram illustrating the flexible transition points in the laser-cut pattern of the hypotube in one of the embodiments.
 - FIG. 43 is a photograph illustrating the degree of angled laser-cut and the degree of uncut in the angled laser-cut delivery system or hypotube in one of the embodiments.
 - FIG. 44 is a schematic diagram illustrating the horizontal laser-cut delivery system in one of the embodiments.

5

FIG. **45** is a schematic diagram illustrating the edges of the kerf in the horizontal laser-cut delivery system or hypotube are rounded or sharp in one of the embodiments.

FIG. **46** is a photograph illustrating the degree of horizontal laser-cut and the degree of uncut in the horizontal laser-cut delivery system or hypotube in one of the embodiments.

FIG. 47 is a schematic diagram illustrating a hybrid delivery system with the filaments or wires that are braided together like a hypotube in one of the embodiments.

FIG. **48** is a schematic diagram illustrating a thrombus or blood clot in the right middle cerebral artery causing an acute ischemic stroke noted during angiography with a guide catheter or a shuttle or a balloon guide catheter positioned in the right internal carotid artery in one of the embodiments.

FIG. **49** is a schematic diagram illustrating a standard ¹⁵ microcatheter being advanced across the thrombus or blood clot in the right middle cerebral artery over a microwire in one of the embodiments.

FIG. **50** is a photograph illustrating the shape-set textile structure based mechanical thrombectomy device in one of ²⁰ the embodiments.

DRAWINGS

Reference Numerals

Part numbers for the Figures are listed below

Part Number	Description
1	Distal Tip
5	Extra small spherical bulbs (d = 3 mm)
10	Small spherical bulbs $(d = 3.5 \text{ mm})$
15	Medium spherical bulbs (d = 4 mm)
20	Large spherical bulbs (d = 4.5 mm)
25	Proximal Marker band
30	Delivery System/Hypotube
35	Extra small vessel segment
40	Small vessel segment
45	Medium vessel segment
50	Large vessel segment
55	Usable length
60	Proximal marker to distal tip length
65	Narrow Distal Neck
70	Wide Distal Neck
75	Extra Small oblong bulbs
80	Small oblong bulbs
85	Medium oblong bulbs
90	Large oblong bulbs
95	Narrow neck between bulbs
100	Non-tapered spherical bulbs (diameter = 1-30 mm)
105	Non-tapered oblong bulbs (diameter = 1-30 mm)
110	Proximal neck
115	Cylindrical shape-set structure
120	Distal marker band
125	Distal spherical filter (diameter = 1-30 mm)
130	Proximal spherical filter (diameter = 1-30 mm)
135 140	Distal oblong filter (diameter = 1-30 mm) Proximal oblong filter (diameter = 1-30 mm)
145	Yarn Wheel
150	Spindle
155	Filament of textile structure
160	Preform point
165	Textile structure
170	Direction of rotation of yarn wheel
175	Cylindrical mandrel
190	Laser cut free end of the textile structure
195	Lead free solder with flux 2 or 3
200	Epoxy glue
205	Any type of bonding agent - solder, epoxy glue etc.
210	Pinched Ring
215	Pinched cylinder
210	II + Cl ' 1 DET + 1

220

225

Heat Shrink PET tube

Overlay bonding zone

6

-continued

Part Number	Description
230	Uncut bonding zone
235	Hypotube through cross-section of textile structure
240	Distal to distal overlay bonding zone
245	Kerf Width
250	Strut Width
251	Strut Width 2
252	Strut Width 3
253	Strut Width 4
255	Laser cut length
260	Anchor point distance (gap between 2 kerfs on same row)
265	Delivery system wall thickness
270	Step 1 of diagonal stagger distance between two rows of
	laser cuts of the same pattern
275	Step 2 of diagonal stagger distance between two rows of
***	laser cuts of the same pattern
280	Direction of pattern A laser cut
285	Direction of pattern B laser cut
295	Length of delivery system
300	Inner diameter circumference of delivery system
305	Outer diameter circumference of delivery system
310	Direction of folding delivery system (Compressing
215	expanded view into cylindrical view of delivery system)
315	Inter-pattern stagger distance between rows
320	Laser cut pattern A
330 335	Laser cut pattern A and B interspersed
333 340	Rounded kerf edge
340 345	Square or sharp kerf edge wires of delivery system
350	Bonding zone of textile structure to delivery system
355	bonding agent for filaments of delivery system
360	Extra small pitches (Kerf width plus strut width)
365	Small pitches (Kerf width plus strut width)
370	Medium pitches (Kerf width plus strut width)
375	Large pitches (Kerf width plus strut width)
580	Guide catheter
590	Microcatheter
600	Microwire
650	Blood clot or Clot burden
000	Dieda vist of Civi bulden

DETAILED DESCRIPTION

FIG. 1 is a schematic diagram that illustrates a two-dimensional front view of one of the embodiments with a spherical tapered textile structure. It has three components in one of the embodiments: a shape-set textile structure, a bonding zone at the region of the proximal marker band, and a delivery system or hypotube.

The shape-set tapered textile structure in several embodiments has a distal tip, that in the expanded configuration has an outer diameter of less than e.g., 0.017 inches (0.43 mm) and in the collapsed configuration has an outer diameter of 50 less than e.g., 0.0125 inches (0.317 mm). In several embodiments, the expanded configuration of the tip has a diameter in the range of about 0.35-0.65 mm (e.g., 0.40-0.45 mm). In several embodiments, the collapsed configuration has a diameter in the range of about 0.1-0.34 mm (e.g., 0.25-0.33 mm). In some embodiments, for larger vessels, the expanded configuration has a diameter in the range of about 1-40 mm and a diameter in the range of about 0.5-10 mm in a collapsed configuration. In some embodiments, the ratio of the expanded configuration to the collapsed configuration is 1.2: 60 1-10:1. In several embodiments, the distal neck is narrow and has similar outer diameter in the expanded and collapsed configuration as the distal tip. The distal neck has a length that ranges from about 1-5 mm in one of the embodiments.

In several embodiments, there are a total of 10 spherical bulbs in one of the embodiments with varying diameters in the expanded configuration and in the collapsed configuration has an outer diameter of less than e.g., 0.0125 inches (0.317).

mm). In several embodiments, the expanded configuration of the bulbs has a diameter in the range of about 1-6 mm (e.g., 3-4.5 mm). In several embodiments, the collapsed configuration has a diameter in the range of about 0.1-0.9 mm (e.g., 0.25-0.5 mm). In some embodiments, for larger vessels, the expanded configuration has a diameter in the range of about 5-40 mm and a diameter in the range of about 0.5-5 mm in a collapsed configuration. In some embodiments, the ratio of the expanded configuration to the collapsed configuration is 1.2:1-10:1.

In some embodiments, the varying outer diameters of the 10 spherical bulbs in the expanded configuration are as follows in one of the embodiments: The distal three extra-small spherical bulbs have an outer diameter (e.g., d=3 mm) in the expanded configuration and corresponds to the extra-small 15 vessel segments such as the M2 segments of the middle cerebral artery, the next three small spherical bulbs have an outer diameter (e.g., d=3.5 mm) in the expanded configuration and corresponds to the smaller vessel segments such as the distal M1 segment of the middle cerebral artery, the next two 20 medium spherical bulbs have an outer diameter (e.g., d=4 mm) in the expanded configuration and corresponds to the medium vessel segments such as the proximal M1 segment of the middle cerebral artery, and the proximal two large spherical bulbs have an outer diameter (d=4.5 mm) in the expanded 25 configuration that corresponds to the large vessel segments such as the distal supra-clinoid segment of the internal carotid artery. This tapered configuration of the shape-set textile structure allows for adequate and safe deployment of the device across blood vessels with multiple diameters. 30 Although specific diameter numbers are provided in this paragraph, other embodiments include diameters that are ± -5 , 10, 15, or 20%.

In some embodiments, 10 bulbs are used. However, in other embodiments, 1-9 bulbs or 11-30 (or more) bulbs may 35 be used. In some embodiments, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 bulbs are used. In some conditions, for example in the leg, where clots can be up 20-40 cm, 40-60 bulbs may be used. In some embodiments, 1 bulb is used for every 0.2-5 cm (e.g., about 0.5-2 cm).

In several embodiments, bulbs of various sizes and/or shapes are provided on a single elongate support structure (such as a neck, tube, spindle, spine, rod, backbone, etc.). The elongate support structure may be hollow, filled or partially hollow. The elongate support structure may have a length in 45 the range of about 1-20 cm (e.g., about 4-8 cm, 5-10 cm, etc). In larger vessels (e.g., outside the brain) the length can be about 20-50 cm. The diameter or width of the elongate support structure is in the range of about 0.35-0.65 mm (e.g., 0.40-0.45 mm) in an expanded configuration and in the range 50 of about 0.1-0.34 mm (e.g., 0.25-0.33 mm) in the collapsed configuration. In some embodiments, for larger vessels, the expanded configuration of the elongate support structure has a diameter in the range of about 1-40 mm (e.g., 5-20 mm) and a diameter in the range of about 0.5-10 mm (e.g., 1-2 mm) in 55 a collapsed configuration. Wall thickness of the elongate support structure are, in some embodiments, ranges from about 0.01-4 mm (e.g., about 0.02-1 mm 0.02-0.05 mm, e.g., 0.025 mm). The elongate support structure may be braided, knitted or weaved with two or more strands (e.g., about 12-120 60 strands, 12-96 strands, 48 strands) in some embodiments. The pattern, in some embodiments, is one-over-one-under-two, one-over-one-under-one, two-over-two-under-two, etc. In some embodiments, the braid angle is in the range of about 45-179 degrees (e.g., about 130-160 degrees, 151 degrees). 65 The picks (or pixels) per inch (PPI) range from about 50-300 PPI (e.g., about 150-190 PPI, e.g., 171 PPI). In some embodi8

ments, increased outward expansile force and/or compression resistance is provided by a higher braid angle and/or higher PPI. In some embodiments, the force/resistance (e.g., radial force) is in a range sufficient to expand a target vessel in the range of about 0%-30%. In some embodiments, the total diameter size of the treatment device is 0.5 mm-1.5 mm greater than the target vessel diameter. In some embodiments, the total diameter size of the treatment device is oversized by 10-50% with respect to the target vessel diameter. The elongate support structure may be made of shape memory alloys (e.g., nickel titanium). In some embodiments, the elongate support structure is about 50-95% (e.g., 75%) nickel titanium and about 5-50% (e.g., 25%) platinum iridium or platinum tungsten or combinations thereof. The radio-opaque portions can be spaced or clustered to increase visibility under x-ray. For example, a thick band pattern may be used which can include 1-12 radio-opaque strands (e.g., filaments, wires, etc.) that are wound adjacently with one another. In several embodiments, the bulbs are integral with the elongate support structure. In other embodiments, the bulbs are coupled (fixably or reversibly coupled) to the elongate support structure.

For example, bulbs size (with respect to the outer diameter in an expanded configuration) is about 0.5-3 mm (e.g., 3 mm), about 3.1-3.9 mm (e.g., 3.5 mm), about 4-4.4 mm (e.g., 4 mm), and about 4.5-7.5 mm (e.g., 4.5 mm) are provided. In some embodiments, the bulbs are sized in the range of about 1 mm-80 mm (e.g., 2 mm-12 mm). Bulbs in range of 4-10 mm may be particular beneficial for larger clots and/or vessels (e.g., in the leg). The sizes above are reduced by 1.3-10 times in the collapsed configuration. In some embodiments, the collapsed configuration of the bulbs is about 50-80% of the inner diameter of the delivery catheter (e.g., microcatheter). In some embodiments, each consecutive bulb is larger than the other. In other embodiments, two sizes are used in an alternate pattern. In yet other embodiments, three or more sizes are used in a series, and each series is repeated two, three, four, five, six, seven, or more times. As an example, if a series of three sizes is alternated, twenty-one bulbs are used. In some embodiments, larger bulbs may be used at the ends, while smaller bulbs are used in the middle. Bulbs may be smaller at the ends and larger in the middle.

Various bulb shapes may be used according to several embodiments, including spherical, oblong, egg, and elliptical (e.g., with respect to top view, side-view and/or cross-section). Square, rectangular and diamond-shapes (e.g., with respect to top view, side-view and/or cross-section) are used in some embodiments. Spiral, twisted, or helical bulbs are provided in some embodiments. For example, sphere-like bulbs and oblong bulbs may be used in a single strand. In some embodiments, shapes are alternated. In yet other embodiments, three or more shapes are used in a series, and each series is repeated two, three, four, five, six, seven, or more times. In some embodiments, bulbs of a first shape may be used at the ends, while bulbs of a second shape are used in the middle. Bulbs may be a first shape at the ends and a second shape in the middle, or vice versa.

The positioning of the bulbs may be beneficial for certain vessel sizes and/or clot locations, material, and/or sizes. Bulbs may be touching (e.g., contiguous) or non-touching. A single strand may include bulbs that are both touching and non-touching. In several embodiments, a strand includes bulbs that are all non-touching and/or are spaced apart by one or more spacers. These spacers may be of the same or different material than the bulbs. The spacers may also be shaped differently than the bulbs. The spacers may comprise, be embedded with or coated by markers or other visualization aids (such as radio-opaque portions).

The bulbs may be separated by distances of about 0.1 to 50 mm, including, but not limited to, about 0.5-1, 1-2, 2-3, 3-4, 4-5, 5-8, 8-10, 10-12, 12-15, 15-25, 25-35, and 35-50 mm apart, including overlapping ranges thereof. The spaces between all the bulbs in one strand may be constant. Alternatively, the spacing between two or more (or all) of the bulbs may be different. In some embodiments, some bulbs are spaced the same distance from one another, while other bulbs have different spacing.

FIG. 2 is a schematic diagram illustrating the 3D perspective view of one of the embodiments with a spherical tapered textile structure.

FIG. 3 is a schematic diagram illustrating the 2D view of one of the embodiments with an oblong tapered textile structure.

FIG. 4 is a schematic diagram illustrating the 3D perspective view of one of the embodiments with an oblong tapered textile structure.

FIG. 5 is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical and oblong inter- 20 spersed tapered textile structure.

FIG. **6** is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical non-tapered textile structure.

FIG. 7 is a schematic diagram illustrating the 2D view of 25 one of the embodiments with an oblong non-tapered textile structure

FIG. **8** is a schematic diagram illustrating the 2D view of one of the embodiments with a spherical and oblong interspersed non-tapered textile structure.

FIG. 9 is a schematic diagram illustrating the 2D view of one of the embodiments with cylindrical wide-mouthed distal tip textile structure.

FIG. 10 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed 35 distal tip textile structure.

FIG. 11 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with a spherical or oblong distal filter textile structure.

FIG. 12 is a schematic diagram illustrating the 2D view of one of the embodiments with a cylindrical narrow-mouthed distal tip with a spherical distal and proximal filter textile structure.

FIG. 13 is a schematic diagram illustrating the 2D view of 45 one of the embodiments with a cylindrical narrow-mouthed distal tip with an oblong distal and proximal filter textile structure.

FIG. **14**A is a schematic diagram illustrating the wires positioned on the yarn to develop a biomedical textile structure in one of the embodiments.

FIG. 14B is a schematic diagram illustrating the braid carrier set up mechanism for the position of the wires on the yarn to develop a biomedical textile structure in one of the embodiments

FIG. 15A is a photograph illustrating the wires being braided into a biomedical textile structure on the yarn in one of the embodiments. FIG. 15B is a photograph illustrating the wires being knitted into a biomedical textile structure in one of the embodiments. FIG. 15C is a photograph illustrating the wires being woven into a biomedical textile structure in one of the embodiments.

FIG. **16** is a photograph illustrating the primary tubular shape set textile structure in one of the embodiments.

FIG. 17 is a schematic diagram illustrating the primary 65 shape setting into the necessary geometries needed to develop the shape-set textile structures in one of the embodiments.

10

FIG. 18 is a photograph illustrating the mandrel used for braiding on the yarn that is then used for primary shape setting into the necessary geometries needed in one of the embodiments.

FIG. 19 is a photograph illustrating secondary shape setting into the necessary geometries needed to develop the shape-set textile structure in one of the embodiments.

FIG. 20 is an X-ray photograph illustrating one of the embodiments where there is grouping of multiple radio-opaque filaments or wires together to form an inter-twining thick band for maximal radio-opacity during fluoroscopy.

Radio-opaque materials, metals or alloys, including but not limited to iridium, platinum, tantalum, gold, palladium, tungsten, tin, silver, titanium, nickel, zirconium, rhenium, bismuth, molybdenum, or combinations of the above etc. to enable visibility during interventional procedures.

FIG. 21 is an X-ray photograph illustrating single filaments inter-twined to provide radio-opacity during fluoroscopy in one of the embodiments.

FIG. 22 is an X-ray photograph illustrating double filaments inter-twined to provide radio-opacity during fluoroscopy in one of the embodiments.

FIG. 23 is a photograph illustrating the need for postprocessing of the free end of the textile structure to keep the filaments or wires from fraying in one of the embodiments. Post-processing of the free end of the textile structure (e.g., the elongate support structure and the bulbs) in some of the embodiments includes dip coating, spray coating, sandwich welding the free end using radio-opaque marker bands. Radio-opaque marker band materials, metals or alloys, including but not limited to iridium, platinum, tantalum, gold, palladium, tungsten, tin, silver, titanium, nickel, zirconium, rhenium, bismuth, molybdenum, or combinations of the above etc. to enable visibility during interventional procedures. In some of the embodiments, radio-opaque marker bands can be sandwich welded to the free end of the textile structure (e.g., the elongate support structure and the bulbs), butt welded to the distal end of the delivery system/hypotube, bonded or soldered to the delivery system or hypotube at regular intervals or laser welded into the kerfs created in the laser cut pattern at regular intervals to help measure a clot length, such radio-opaque markers at regular intervals may be separated by distances of about 0.1 to 50 mm, including, but not limited to, about 0.5-1, 1-2, 2-3, 3-4, 4-5, 5-8, 8-10, 10-12, 12-15, 15-25, 25-35, and 35-50 mm apart, including overlapping ranges thereof.

The dip coating or spray coating may comprise a biomedical polymer, e.g., silicone, polyurethane, polyethylene (RexellTM made by Huntsman), polypropylene, polyester (HytrilTM made by Dupont), poly tetra fluoro-ethylene (PTFE), polyvinyl chloride (PVC), polyamides (DurethanTM made by Bayer), polycarbonate (CorethaneTM made by Corvita Corp), or polyethylene-terephthalate. The dip coating or spray coating may further comprise a radio-opaque material, e.g., particles of tantalum, particles of gold, other radio-opaque agents, e.g., barium sulfate, tungsten powder, bismuth subcarbonate, bismuth oxychloride, iodine containing agents such as iohexol (OmnipaqueTM Amersham Health).

FIG. 24 is a schematic diagram illustrating the appearance of the free end of the textile structure (e.g., the elongate support structure and the bulbs) after laser cutting the free end to keep the filaments or wires from fraying in one of the embodiments.

FIG. **25** is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using

solder in one of the embodiments. The solder may be a silverbased lead free solder in some embodiments. The shape-set textile structure may be substantially or fully oxide free when bonding the shape-set textile structure to the delivery system when using such solder.

FIG. 26 is a schematic diagram illustrating the overall ratio of the cross-sectional area between the filaments or wires of the textile structure (e.g., the elongate support structure and the bulbs) and the bonding agent in one of the embodiments.

FIG. 27A is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure and delivery system using epoxy agents in one of the embodiments. FIG. 27B is a photograph illustrating the inlay bonding approach between the shape-set textile structure and delivery system using epoxy agents in one of the embodi-

FIG. 28 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure (e.g., the elongate support structure and the bulbs) and delivery system 20 using a pinched ring as well as a bonding agent in one of the embodiments.

FIG. 29 is a schematic diagram illustrating the inlay bonding approach between the shape-set textile structure (e.g., the elongate support structure and the bulbs) and delivery system 25 (e.g., a hypotube, wire or multi-filament hybrid) using a pinched tube as well as a bonding agent in one of the embodiments. In some of the embodiments, inlay bonding approach includes laser welding, laser butt welding, laser rivet welding, and mechanical crimping of a flared distal end of the hypo-30 tube on the inlayed proximal neck of the textile structure (e.g., the elongate support structure and the bulbs).

FIG. 30 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure (e.g., the elongate support structure and the 35 bulbs) and the distal end of the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using solder in one of the

FIG. 31 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set 40 laser-cut delivery system in one of the embodiments. textile structure (e.g., the elongate support structure and the bulbs) and the distal end of the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using epoxy in one of the embodiments.

FIG. 32 is a schematic diagram illustrating the overlay 45 bonding approach between the proximal neck of the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the non-laser cut distal tip of the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using epoxy in one of the embodiments.

FIG. 33 is a schematic diagram illustrating the overlay bonding approach between the proximal neck of the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the distal end of the delivery system (e.g., a hypotube, wire or multi-filament hybrid) using epoxy and heat 55 shrink tubing in one of the embodiments.

FIG. 34 is a schematic diagram illustrating the overlay bonding approach between the distal neck of the shape-set textile structure (e.g., the elongate support structure and the bulbs) and the distal end of the delivery system (e.g., a hypo- 60 tube, wire or multi-filament hybrid) using bonding agent in one of the embodiments. In some of the embodiments, overlay bonding approach includes laser welding, laser butt welding, laser rivet welding, and mechanical crimping of a flared distal end of the hypotube on the inlayed proximal neck of the textile structure (e.g., the elongate support structure and the bulbs).

12

FIG. 35 is a photography illustrating the angled flexible laser-cut hypotube delivery system in one of the embodi-

Various components (e.g., the elongate support structure, the bulbs, the sheath or the delivery system such as the hypotube) may be made up of materials that are biocompatible or surface treated to produce biocompatibility. Suitable materials include e.g., platinum, titanium, nickel, chromium, cobalt, tantalum, tungsten, iron, manganese, molybdenum, and alloys thereof including nitinol, chromium cobalt, stainless steel, etc. Suitable materials also include combinations of metals and alloys. Suitable materials also include polymers such as polylactic acid (PLA), polyglycolic acid (PGA), polyclycoloc-lactic acid (PLGA), polycaprolactone (PCL), polyorthoesters, polyanhydrides, and copolymers thereof. In some embodiments, the thrombectomy device is made of nitinol and platinum tungsten.

FIG. 36 is a schematic diagram illustrating dimensions for laser-cut Pattern A in one of the embodiments.

FIG. 37 is a schematic diagram illustrating dimensions for laser-cut Pattern B in one of the embodiments.

FIG. 38 is a schematic diagram illustrating the directional stagger of laser-cut Pattern A and Pattern B in one of the embodiments.

FIG. 39 is a schematic diagram illustrating the interspersed laser-cut Pattern A and B in one of the embodiments.

FIG. 40 is a schematic diagram illustrating the interspersed laser-cut Pattern A and B with the inter-pattern stagger in one of the embodiments.

FIG. 41 is a schematic diagram illustrating the edges of the kerf in the angled laser-cut delivery system or hypotube are rounded or sharp in one of the embodiments.

FIG. 42 is a schematic diagram illustrating the flexible transition points in the laser-cut pattern of the hypotube in one of the embodiments.

FIG. 43 is a photograph illustrating the degree of angled laser-cut and the degree of uncut in the angled laser-cut delivery system or hypotube in one of the embodiments.

FIG. 44 is a schematic diagram illustrating the horizontal

FIG. 45 is a schematic diagram illustrating the edges of the kerf in the horizontal laser-cut delivery system or hypotube are rounded or sharp in one of the embodiments.

FIG. 46 is a photograph illustrating the degree of horizontal laser-cut and the degree of uncut in the horizontal laser-cut delivery system or hypotube in one of the embodiments.

FIG. 47 is a schematic diagram illustrating a hybrid delivery system with the filaments or wires that are braided together like a hypotube in one of the embodiments.

FIG. 48 is a schematic diagram illustrating a thrombus or blood clot in the right middle cerebral artery causing an acute ischemic stroke noted during angiography with a guide catheter or a shuttle or a balloon guide catheter positioned in the right internal carotid artery in one of the embodiments.

FIG. 49 is a schematic diagram illustrating a catheter (e.g., microcatheter) being advanced across the thrombus or blood clot in the right middle cerebral artery over a microwire in one of the embodiments. The microwire is then removed and the mechanical thrombectomy device is advanced through the hub of the microcatheter via an introducer sheath that is protective encasing for the flexible delivery system. In several embodiments, the catheter (e.g., microcatheter) is reinforced with the laser cut hypotube so as to, in one embodiment, inherit the maneuverability advantages of the hypotube (e.g., to facilitate proximal support and distal flexibility). In some embodiments, a catheter with varying pitches is used. For example, the pitch from the distal end to the proximal end

varies as follows: about 0.005 inch, 0.01 inch, 0.02 inch, 0.04 inch, 0.08 inch and 0.16 inch. In some embodiments, the pitch from the distal end to the proximal end varies as follows: about 0.005 inch for the distal most 20%, 0.01 inch for the next 15%, 0.02 inch for the next 15%, 0.04 inch for the next 5%, 0.08 inch for the next 15%, and 0.16 inch for the next (or proximal-most) 20%.

13

The introducer sheath may comprise a biomedical polymer, e.g., silicone, polyurethane, polyethylene (RexellTM made by Huntsman), polypropylene, polyester (HytrilTM 10 made by Dupont), poly tetra fluoro-ethylene (PTFE), polyvinyl chloride (PVC), polyamides (DurethanTM made by Bayer), polycarbonate (CorethaneTM made by Corvita Corp), or polyethylene-terephthalate. Combinations of two or more of these materials may also be used.

The microcatheter may comprise a biomedical polymer, e.g., silicone, polyurethane, polyethylene (RexellTM made by Huntsman), polypropylene, polyester (HytrilTM made by Dupont), poly tetra fluoro-ethylene (PTFE), polyvinyl chloride (PVC), polyamides (DurethanTM made by Bayer), polycarbonate (CorethaneTM made by Corvita Corp), or polyethylene-terephthalate. Combinations of two or more of these materials may also be used.

FIG. **50** is a photograph illustrating the shape-set textile structure based mechanical thrombectomy device in one of 25 the embodiments.

In several embodiments, the devices described herein can be used in the brain. In some embodiments, vasculature in the periphery can be treated. In some embodiments, coronary vessels are treated. Abdominal aorta and branches are treated 30 in several embodiments.

In some embodiments, a subject having a clot is identified. An access catheter is advanced over a guidewire to a vessel proximate or containing the clot. The guidewire may be removed at this stage. A microcatheter is advanced over a 35 microwire, but stop before or at the clot. The microwire then crosses the clot by 0.5-5 mm (e.g., slices through the center of the clot). The microcatheter is then advanced over the microwire to cross the clot. The microwire is then removed or retracted. The thrombectomy device (the elongate support 40 structure with the bulbs bonded to a delivery system, such as a hypotube, wire or multi-filament wire/hypotube device), as disclosed in several embodiments herein is positioned within an introducer sheath, and together are advanced through the hub of the microcatheter. The thrombectomy device is then 45 advanced through the microcatheter, and the introducer sheath is removed. The thrombectomy device is advanced until it is at the tip of the microcatheter (which is beyond the clot). The thrombectomy device is kept in position, and the microcatheter is retracted (e.g., unsleeved, unsheathed) until 50 the thrombectomy device is expanded. The length of retraction is related to length of the clot in one embodiment (e.g., the microcatheter is retracted to or before the proximal end of the clot). The thrombectomy device is torqued (e.g., in a counterclockwise motion) to facilitate torsional rasping (e.g., 55 rotationally scraping), thereby allowing the bulb(s) to entrap the clot, and collect any debris (emboli). The sticky portions of the clot, which can be attached to the endothelium wall, can be removed by the torquing motion. The non-laser cut braided nature of the bulbs facilaite gentle entrapment of the clot 60 without perforating the blood vessel. In one embodiment, a 360 degree rotation on the proximal end results in a distal rotation that is less than 360 degrees (e.g., 90-180 degrees). In several embodiments, the rotational force from the proximal end to the distal is not 1:1. Instead the ratio is 1:0.75, 1:0.5 or 65 1:0.25. This non-1:1 ratio, in some embodiments, is beneficial because it provides a gentle rotation that reduces the risk

14

that the blood vessel is rotated, displaced, disrupted or perforated. In several embodiments, if one bulb cannot fully entrap the clot, another bulb (whether it is the same or different in size and/or shape) will be able to further entrap the clot. In some embodiments, the undulations (e.g., the hills and valleys created by the bulbs and support structure) facilitate clot entrapment. Undulation is also provided at a micro level by the braiding pattern. This dual-undulating pattern enhances scraping and entrapment in several embodiments. The clot, once entrapped or captured by the bulbs, can then be removed as the thrombectomy device is removed from the subject. The thrombectomy device is removed as follows in some embodiments: the microcatheter and the delivery system (e.g., hypotube) are retracted into the tip of the guide catheter while negative suction is applied (e.g., with a syringe) at the level of the guide catheter and also while the microcatheter is retracted at a similar rate such that the microcatheter does not generally recapture any expanded portion of the thrombectomy device or expand (or expose) additional portions of the thrombectomy device. In other words, unexpanded bulbs remain unexpanded and expanded bulbs remain expanded until they are retracted into the guide catheter. Suction can be applied for about 5-30 seconds using a 30-90 cc syringe. The steps above need not be performed in the order recited.

The following references are herein incorporated by reference: (1) Sarti C, Rastenyte D, Cepaitis Z, Tuomilehto J. International trends in mortality from stroke, 1968 to 1994. Stroke. 2000; 31:1588-1601; (2) Wolf PA, D'Agostino RB. Epidemiology of Stroke. In: Barnett H J M, Mohr J P, Stein B M, Yatsu F, eds. Stroke: Pathophysiology, Diagnosis, and Management. 3rd ed. New York, N.Y.: Churchill Livingstone; 1998:6-7; (3) Adams H P, Jr., Adams R J, Brott T, del Zoppo G J, Furlan A, Goldstein L B, Grubb R L, Higashida R, Kidwell C, Kwiatkowski T G, Marler J R, Hademenos G J. Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke. 2003; 34:1056-1083; (4) Rymer M M, Thrutchley D E. Organizing regional networks to increase acute stroke intervention. Neurol Res. 2005; 27:59-16; and (5) Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, Pessin M, Ahuj a A, Callahan F, Clark W M, Silver F, Rivera F. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Jama. 1999; 282:2003-2011.

While the invention is susceptible to various modifications, and alternative forms, specific examples thereof have been shown in the drawings and are herein described in detail. It should be understood, however, that the invention is not to be limited to the particular forms or methods disclosed, but to the contrary, the invention is to cover all modifications, equivalents and alternatives falling within the spirit and scope of the various embodiments described and the appended claims. The ranges disclosed herein also encompass any and all overlap, sub-ranges, and combinations thereof. Language such as "up to," "at least," "greater than," "less than," "between," and the like includes the number recited. Numbers preceded by a term such as "about" or "approximately" include the recited numbers. For example, "about 3 mm" includes "3 mm."

What is claimed is:

- 1. A thrombectomy device comprising:
- an elongate support structure comprising a plurality of shape-memory and radiopaque wires woven to form a textile fabric having a collapsed state and an expanded state, the elongate support structure comprising:
 - a plurality of self-expanding generally spherical bulbs in the expanded state comprising:

a first bulb:

- a second bulb distal to the first bulb, the first bulb and the second bulb having a first diameter;
- a third bulb distal to the second bulb:
- a fourth bulb distal to the third bulb, the third bulb and 5 the fourth bulb having a second diameter smaller than the first diameter;
- a fifth bulb distal to the fourth bulb;
- a sixth bulb distal to the fifth bulb:
- a seventh bulb distal to the sixth bulb, the fifth bulb, the sixth bulb, and the seventh bulb having a third diameter smaller than the second diameter;

an eighth bulb distal to the seventh bulb;

a ninth bulb distal to the eighth bulb; and

the ninth bulb, and the tenth bulb having a fourth diameter smaller than the third diameter,

necks longitudinally between and radially inward of the self-expanding bulbs, and

a distal neck distal to and radially inward of a distal-most 20 bulb of the self-expanding bulbs, the distal neck comprising a coated distal end;

- a delivery system comprising a hypotube comprising two longitudinally interspersed and circumferentially staggered cut patterns, the cut patterns each comprising a 25 plurality of rows each comprising two longitudinallyspaced kerfs angled with respect to a longitudinal axis of the hypotube and comprising rounded edges, wherein a longitudinally-spacing of the kerfs varies along the hypotube; and
- a bonding zone where the delivery system is coupled to the elongate support structure, the bonding zone comprising a radiopaque marker band.
- 2. The device of claim 1, wherein an outer diameter of the elongate support structure in the collapsed state is less than 35 about 0.0125 inches.
- 3. The device of claim 1, wherein an outer diameter of the elongate support structure in the collapsed state is in a range of about 0.1-0.9 mm.
- **4**. The device of claim **1**, wherein the first diameter is about 40 4.5 mm, the second diameter is about 4 mm, the third diameter is about 3.5 mm, and the fourth diameter is about 3 mm.
 - **5**. A thrombectomy device comprising:
 - an elongate support structure comprising a plurality of wires woven to form a textile fabric having a collapsed 45 state and an expanded state, the elongate support struc-

16

ture comprising a plurality of longitudinally-spaced self-expanding bulbs in the expanded state, wherein the plurality of bulbs comprises five to ten bulbs, and wherein at least two of the plurality of bulbs have different outer diameters in the expanded state; and

a delivery system comprising a hypotube comprising a plurality of longitudinally interspersed cut patterns each comprising a plurality of rows of longitudinally-spaced kerfs.

6. The device of claim 5, wherein the plurality of bulbs comprises ten bulbs.

7. The device of claim 5, wherein at least two of the plurality of bulbs have different shapes in the expanded state.

8. The device of claim 5, wherein at least one of the plua tenth bulb distal to the ninth bulb, the eighth bulb, 15 rality of bulbs has a spherical shape in the expanded state.

9. The device of claim 5, wherein at least one of the plurality of bulbs has a oblong shape in the expanded state.

10. The device of claim 5, wherein longitudinal spacing between the plurality of bulbs is constant.

11. The device of claim 5, wherein the plurality of wires comprises shape memory and radiopaque wires.

12. The device of claim 11, wherein the radiopaque wires are clustered to enhance visibility under x-ray.

13. The device of claim 5, wherein an outer diameter of the elongate support structure in the collapsed state is less than about 0.0125 inches.

14. The device of claim 5, wherein each of the rows is angled with respect to a longitudinal axis of the hypotube.

15. The device of claim 5, wherein the kerfs comprise 30 rounded edges.

16. The device of claim 5, wherein the plurality of bulbs comprises five bulbs.

17. The device of claim 5, wherein the plurality of bulbs comprises six bulbs.

18. The device of claim 5, wherein the outer diameters of the plurality of bulbs are tapered from a largest outer diameter of the proximal-most bulb to a smallest outer diameter of a distal-most bulb.

19. The device of claim 5, wherein the plurality of wires comprises a first plurality of wires comprising shape-memory material and a second plurality of wires comprising radiopaque material.

20. The device of claim 19, wherein at least some of the second plurality of wires are grouped to form a radiopaque band under fluoroscopy.